Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)?

• Pharvaris N.V. recently reported full-year 2025 results showing a net loss of €175.7 million, with basic and diluted loss per share from continuing operations of €2.97, while advancing its hereditary angioedema (HAE) pipeline.
• Despite deeper losses, Pharvaris completed enrollment in its CHAPTER-3 pivotal study of deucrictibant XR and stayed on track for a near-term regulatory filing for deucrictibant IR, underscoring the company’s focus on progressing multiple HAE treatment approaches.
• We’ll now examine how completing enrollment in the CHAPTER-3 pivotal study could influence Pharvaris’ investment narrative and future positioning.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 26 companies in the world exploring or producing it. Find the list for free.

What Is Pharvaris' Investment Narrative?

To own Pharvaris, you have to believe that its deucrictibant franchise can evolve into a meaningful hereditary angioedema treatment platform despite ongoing losses and zero revenue today. The completion of enrollment in CHAPTER-3, alongside progress toward an NDA filing for deucrictibant IR, reinforces that the key near-term catalysts still center on pivotal data readouts and regulatory decisions rather than financial metrics. At the same time, the wider 2025 net loss of €175.7 million highlights how dependent the story is on timely approvals and eventual market uptake to support further development without excessive dilution. In that context, the recent news is material because it reduces execution risk around trial timelines, while also sharpening the spotlight on regulatory, competitive, and financing risks over the next 12 to 24 months.

However, one of the financing-related risks here is easy to miss at first glance. Pharvaris' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

The Simply Wall St Community currently offers 1 fair value view, clustered around US$45.97 per share, underlining how even a single perspective can differ from market pricing. Set this against Pharvaris’ deeper 2025 loss and trial dependent catalysts and it is clear you should compare multiple viewpoints before drawing conclusions about the company’s long term potential.

Explore another fair value estimate on Pharvaris - why the stock might be worth as much as 61% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Pharvaris research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Pharvaris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pharvaris' overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
• Find 59 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com